Jonathan P. Graham, Executive Vice President and General Counsel at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $158 billion and "GOOD" financial ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...